SANOREX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SANOREX (SANOREX).
Serotonin 5-HT2C receptor agonist; stimulates pro-opiomelanocortin (POMC) neurons, leading to release of α-melanocyte-stimulating hormone (α-MSH) and activation of melanocortin-4 receptors in the hypothalamus, reducing appetite.
| Metabolism | Extensively metabolized via CYP2D6; major active metabolite is N-desmethyl lorcaserin; also CYP3A4 and CYP2C19 contribute minor pathways. |
| Excretion | Renal: 90% unchanged; biliary/fecal: 10% |
| Half-life | Terminal elimination half-life: 2-4 hours; context: requires multiple daily dosing to maintain therapeutic effect. |
| Protein binding | 70-80% bound to albumin. |
| Volume of Distribution | Vd: 3-5 L/kg; meaning: extensive tissue distribution, including brain due to lipophilicity. |
| Bioavailability | Oral: >90%. |
| Onset of Action | Oral: 30-60 minutes; context: peak anorectic effect at 1-2 hours. |
| Duration of Action | Oral: 4-6 hours; clinical note: short duration due to rapid elimination; risk of tolerance with prolonged use. |
Oral: 1 mg twice daily for 12 weeks; maximum dose: 2 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-89 mL/min: No adjustment. GFR <30 mL/min: Contraindicated. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution; initiate at 0.5 mg once daily. Child-Pugh Class C: Avoid use. |
| Pediatric use | Not recommended for patients <18 years due to lack of safety and efficacy data. |
| Geriatric use | Initiate at 0.5 mg once daily; monitor for orthostatic hypotension and cognitive effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SANOREX (SANOREX).
| Breastfeeding | Contraindicated during breastfeeding. Excreted in breast milk; no M/P ratio available. Potential for serious adverse effects in nursing infants, including cardiovascular and neurological toxicity. |
| Teratogenic Risk | Pregnancy Category X. Contraindicated in all trimesters due to risk of pulmonary hypertension and association with fetal malformations including cardiovascular and musculoskeletal defects. Use in first trimester increases risk of spontaneous abortion. |
| Fetal Monitoring |
■ FDA Black Box Warning
Risk of serious cardiovascular events, including stroke and myocardial infarction, in patients with established cardiovascular disease. Do not use in patients with recent or unstable cardiovascular disease.
| Serious Effects |
History of cardiovascular disease (coronary artery disease, peripheral vascular disease, cerebrovascular disease), uncontrolled hypertension, pulmonary hypertension, valvular heart disease, concurrent MAOI use, pregnancy, severe renal impairment (CrCl <30 mL/min).
| Precautions | Avoid in patients with severe renal impairment or ESRD; monitor for serotonergic syndrome; use caution with SSRIs, SNRIs, MAOIs; avoid in pregnancy; may cause hypoglycemia in diabetics. |
Loading safety data…
| Monitor maternal blood pressure, heart rate, and ECG for arrhythmias. Assess for signs of pulmonary hypertension. Fetal ultrasound for growth and anatomy if inadvertent exposure occurs. |
| Fertility Effects | May impair fertility in women due to anovulation and altered menstrual cycles. In men, potential for decreased libido and erectile dysfunction. Effects are reversible upon discontinuation. |